Evaluating the FDA regenerative medicine framework: opportunities for stakeholders

Regen Med. 2020 Jul;15(7):1825-1832. doi: 10.2217/rme-2020-0073. Epub 2020 Aug 20.

Authors

Elizabeth Richardson¹, Farzana Akkas², Zubin Master³

Affiliations

¹ Director, Health Care Products Project, The Pew Charitable Trusts, 901 E Street, NW, Washington, DC 20004-2008, USA.
² Senior Research Associate, Health Care Products Project, The Pew Charitable Trusts, 901 E Street, NW, Washington, DC 20004-2008, USA.
³ Associate Professor, Biomedical Ethics Research Program & Center for Regenerative Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA.

PMID: 32815780
DOI: 10.2217/rme-2020-0073

No abstract available

Keywords: FDA; drug regulation; laws; regenerative medicine; unproven stem cell interventions.

Publication types

Editorial

MeSH terms

Humans
Regenerative Medicine / legislation & jurisprudence
Regenerative Medicine / organization & administration*
Stem Cell Transplantation / methods*
United States
United States Food and Drug Administration / organization & administration*